Affiliation(s):
Department of Urology, Tianjin First Central Hospital, Tianjin 300000, China;
moreAffiliation(s): Department of Urology, Tianjin First Central Hospital, Tianjin 300000, China; Department of Urology, First Central Clinical College, Tianjin Medical University, Tianjin 300000, China;
less
Sheng ZENG, Shaoqiang XING, Yifei ZHANG, Haifeng WANG,Qian LIU. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2300392
@article{title="Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment", author="Sheng ZENG, Shaoqiang XING, Yifei ZHANG, Haifeng WANG,Qian LIU", journal="Journal of Zhejiang University Science B", year="in press", publisher="Zhejiang University Press & Springer", doi="https://doi.org/10.1631/jzus.B2300392" }
%0 Journal Article %T Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment %A Sheng ZENG %A Shaoqiang XING %A Yifei ZHANG %A Haifeng WANG %A Qian LIU %J Journal of Zhejiang University SCIENCE B %P %@ 1673-1581 %D in press %I Zhejiang University Press & Springer doi="https://doi.org/10.1631/jzus.B2300392"
TY - JOUR T1 - Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment A1 - Sheng ZENG A1 - Shaoqiang XING A1 - Yifei ZHANG A1 - Haifeng WANG A1 - Qian LIU J0 - Journal of Zhejiang University Science B SP - EP - %@ 1673-1581 Y1 - in press PB - Zhejiang University Press & Springer ER - doi="https://doi.org/10.1631/jzus.B2300392"
Abstract: Cancer immunotherapy has rapidly become the fourth mainstream treatment alternative after surgery, radiotherapy and chemotherapy, with some promising results. It aims to kill tumor cells by mobilizing or stimulating cytotoxic immune cells. However, the clinical applications of tumor immunotherapies are limited owing to a lack of adequate delivery pathways and high toxicity. Recently, nanomaterials and genetic engineering have shown great potential in overcoming these limitations by protecting the delivery of antigens, activating targeted T cells, modulating the immunosuppressive tumor microenvironment, and improving the treatment efficacy. Bacillus Calmette-Guérin (BCG) is a live attenuated Mycobacterium bovis vaccine used to prevent tuberculosis, which was first reported to have antitumor activity in 1927. BCG therapy can activate the immune system by inducing various cytokines and chemokines, and its specific immune and inflammatory response exerts antitumor effects. BCG was first used during the 1970s as an intravesical treatment agent for bladder cancer, which effectively improved immune antitumor activity and prevented tumor recurrence. More recently, nano-BCG and genetically engineered BCG have been proposed as treatment alternatives for bladder cancer due to their ability to induce stronger and more stable immune responses. In this study, we outline the development of nano-BCG and genetically engineered BCG for bladder cancer immunotherapy and review their potential and associated challenges.
Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference
Open peer comments: Debate/Discuss/Question/Opinion
Open peer comments: Debate/Discuss/Question/Opinion
<1>